Literature DB >> 18622177

Sensitivity to delta9-tetrahydrocannabinol is selectively enhanced in beta-arrestin2 -/- mice.

Christopher S Breivogel1, Jonathan M Lambert, Steven Gerfin, John W Huffman, Raj K Razdan.   

Abstract

Little is known about the roles of beta-arrestins in the regulation of brain CB1 cannabinoid receptors. This study investigated the role of beta-arrestin2 in cannabinoid behavioral effects using beta-arrestin2 -/- mice and their wild-type counterparts. A variety of cannabinoid ligands from different chemical classes that exhibit a variety of efficacies for activation of CB1 receptors were investigated, including Delta-tetrahydrocannabinol, CP55940, methanandamide, JWH-073, and O-1812. Delta-tetrahydrocannabinol produced both greater antinociception and greater decreases in body temperature in beta-arrestin2 -/- compared with beta-arrestin2 +/+ mice. No significant differences were, however, present in either assay for the other CB1 agonists. Antagonist radioligand binding indicated no difference in the density of cannabinoid CB1 receptors in the cerebellum, cortex, or hippocampus of beta-arrestin2 +/+ and -/- mice. These data demonstrate that beta-arrestin2 may regulate cannabinoid CB1 receptor sensitivity in an agonist-specific manner.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18622177      PMCID: PMC2751575          DOI: 10.1097/FBP.0b013e328308f1e6

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  40 in total

1.  Enhanced morphine analgesia in mice lacking beta-arrestin 2.

Authors:  L M Bohn; R J Lefkowitz; R R Gainetdinov; K Peppel; M G Caron; F T Lin
Journal:  Science       Date:  1999-12-24       Impact factor: 47.728

2.  Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence.

Authors:  L M Bohn; R R Gainetdinov; F T Lin; R J Lefkowitz; M G Caron
Journal:  Nature       Date:  2000-12-07       Impact factor: 49.962

Review 3.  Cannabis: pharmacology and toxicology in animals and humans.

Authors:  I B Adams; B R Martin
Journal:  Addiction       Date:  1996-11       Impact factor: 6.526

4.  Bone response to intermittent parathyroid hormone is altered in mice null for {beta}-Arrestin2.

Authors:  S L Ferrari; D D Pierroz; V Glatt; D S Goddard; E N Bianchi; F T Lin; D Manen; M L Bouxsein
Journal:  Endocrinology       Date:  2005-02-10       Impact factor: 4.736

5.  Morphine side effects in beta-arrestin 2 knockout mice.

Authors:  Kirsten M Raehal; Julia K L Walker; Laura M Bohn
Journal:  J Pharmacol Exp Ther       Date:  2005-05-25       Impact factor: 4.030

6.  Development of cross-tolerance between delta 9-tetrahydrocannabinol, CP 55,940 and WIN 55,212.

Authors:  F Fan; D R Compton; S Ward; L Melvin; B R Martin
Journal:  J Pharmacol Exp Ther       Date:  1994-12       Impact factor: 4.030

7.  Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities.

Authors:  D R Compton; K C Rice; B R De Costa; R K Razdan; L S Melvin; M R Johnson; B R Martin
Journal:  J Pharmacol Exp Ther       Date:  1993-04       Impact factor: 4.030

8.  (R)-methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability.

Authors:  V Abadji; S Lin; G Taha; G Griffin; L A Stevenson; R G Pertwee; A Makriyannis
Journal:  J Med Chem       Date:  1994-06-10       Impact factor: 7.446

9.  Cannabinoid receptor agonist efficacy for stimulating [35S]GTPgammaS binding to rat cerebellar membranes correlates with agonist-induced decreases in GDP affinity.

Authors:  C S Breivogel; D E Selley; S R Childers
Journal:  J Biol Chem       Date:  1998-07-03       Impact factor: 5.157

10.  Cannabinoid receptor localization in brain.

Authors:  M Herkenham; A B Lynn; M D Little; M R Johnson; L S Melvin; B R de Costa; K C Rice
Journal:  Proc Natl Acad Sci U S A       Date:  1990-03       Impact factor: 11.205

View more
  29 in total

1.  Serotonin, but not N-methyltryptamines, activates the serotonin 2A receptor via a ß-arrestin2/Src/Akt signaling complex in vivo.

Authors:  Cullen L Schmid; Laura M Bohn
Journal:  J Neurosci       Date:  2010-10-06       Impact factor: 6.167

Review 2.  Cannabinoid CB1 receptor-interacting proteins: novel targets for central nervous system drug discovery?

Authors:  Tricia H Smith; Laura J Sim-Selley; Dana E Selley
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

3.  β-arrestin2 regulates cannabinoid CB1 receptor signaling and adaptation in a central nervous system region-dependent manner.

Authors:  Peter T Nguyen; Cullen L Schmid; Kirsten M Raehal; Dana E Selley; Laura M Bohn; Laura J Sim-Selley
Journal:  Biol Psychiatry       Date:  2012-01-20       Impact factor: 13.382

4.  Approaches to Assess Biased Signaling at the CB1R Receptor.

Authors:  Robert B Laprairie; Edward L Stahl; Laura M Bohn
Journal:  Methods Enzymol       Date:  2017-07-05       Impact factor: 1.600

Review 5.  Functional selectivity at G-protein coupled receptors: Advancing cannabinoid receptors as drug targets.

Authors:  Srikrishnan Mallipeddi; David R Janero; Nikolai Zvonok; Alexandros Makriyannis
Journal:  Biochem Pharmacol       Date:  2016-11-24       Impact factor: 5.858

6.  FAAH-/- mice display differential tolerance, dependence, and cannabinoid receptor adaptation after delta 9-tetrahydrocannabinol and anandamide administration.

Authors:  Katherine W Falenski; Andrew J Thorpe; Joel E Schlosburg; Benjamin F Cravatt; Rehab A Abdullah; Tricia H Smith; Dana E Selley; Aron H Lichtman; Laura J Sim-Selley
Journal:  Neuropsychopharmacology       Date:  2010-03-31       Impact factor: 7.853

7.  Opposite function of dopamine D1 and N-methyl-D-aspartate receptors in striatal cannabinoid-mediated signaling.

Authors:  Tanya L Daigle; William C Wetsel; Marc G Caron
Journal:  Eur J Neurosci       Date:  2011-11       Impact factor: 3.386

8.  Characterization of structurally novel G protein biased CB1 agonists: Implications for drug development.

Authors:  Benjamin M Ford; Lirit N Franks; Sherrica Tai; William E Fantegrossi; Edward L Stahl; Michael D Berquist; Christian V Cabanlong; Catheryn D Wilson; Narsimha R Penthala; Peter A Crooks; Paul L Prather
Journal:  Pharmacol Res       Date:  2017-08-23       Impact factor: 7.658

Review 9.  Endogenous lipid activated G protein-coupled receptors: emerging structural features from crystallography and molecular dynamics simulations.

Authors:  Dow P Hurst; Marianne Schmeisser; Patricia H Reggio
Journal:  Chem Phys Lipids       Date:  2013-02-26       Impact factor: 3.329

Review 10.  β-arrestins: regulatory role and therapeutic potential in opioid and cannabinoid receptor-mediated analgesia.

Authors:  Kirsten M Raehal; Laura M Bohn
Journal:  Handb Exp Pharmacol       Date:  2014
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.